X
[{"orgOrder":0,"company":"FutureGen","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gracell Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"FutureGen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,710.0 million","upfrontCash":"$150.0 million","newsHeadline":"AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for IBD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by FutureGen
Filters
Companies By Therapeutic Area
Details:
Under the terms of the agreement, AbbVie will receive an exclusive global license to develop, manufacture, and commercialize FG-M701 for the treatment of inflammatory bowel disease.
Lead Product(s):
FG-M701
Therapeutic Area: Gastroenterology
Product Name: FG-M701
Highest Development Status: IND Enabling
Product Type: Large molecule
Partner/Sponsor/Collaborator:
AbbVie Inc
Deal Size: $1,710.0 million
Upfront Cash: $150.0 million
Deal Type: Licensing Agreement
June 13, 2024
Details:
The collaboration aims to leverage Gracell's extensive experience in immune cell therapy in synergy with FutureGen's fully human CLDN18.2 antibodies to develop, manufacture & commercialize novel immune cell therapies for the treatment of patients with CLDN18.2 positive cancer.
Lead Product(s):
Immune Cell Therapies
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Gracell Biotechnologies
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
August 16, 2021